3
3T Biosciences
An immunotherapy company headquartered in Menlo Park, California
About 3T Biosciences
3T Biosciences is a pioneering company in the field of targeted biotherapeutics, specifically focusing on oncology. The company operates in the healthcare and biotechnology market, serving patients with solid tumors. Utilizing a proprietary screening platform and advanced computational technology, 3T Biosciences identifies prevalent T cell receptor (TCR) targets to develop effective therapies. Their immune response-guided target identification approach allows them to pinpoint the most prevalent targets and pharmacologically active TCRs in patients who have responded well to immune checkpoint inhibitor (CPI) treatments. In addition to TCR T cell therapies, the company also develops high-affinity pHLA binders, enabling therapeutic modalities such as antibody-drug conjugates (ADC), bispecifics, and CAR T cells to selectively target tumors while sparing normal tissues. This approach mitigates the toxicities that have historically limited the success of such therapies in clinical settings. The business model revolves around advancing these innovative therapies through clinical trials and eventually bringing them to market, thereby generating revenue through successful commercialization and partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- South San Francisco, United States
- Employees
- 25
- Open positions
- 1
- Dealroom signal
- 65.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2022 | $40M | $160M | Westlake Village BioPartners · Lightspeed Venture Partners | ↗ |
| SEEDOther financing | Oct 2017 | $12M | $48M | CRV | — |
Growth signals
Latest recorded traffic for 3T Biosciences is 2.3K monthly website visits, up 53.3% over the last three months. 3T Biosciences's team declined 19.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Asset Management Ventures
Westlake Village BioPartners
Lightspeed Venture Partners
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about 3T Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 3T Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.